The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer

2020 ◽  
pp. 78-86
Author(s):  
Lisa Licitra ◽  
Carlo Resteghini ◽  
Paolo Bossi
Keyword(s):  
Systemic Therapy ◽  
Primary Treatment ◽  
Sinonasal Cancer

The role of systemic therapy in the management of sinonasal cancer: A critical review

2015 ◽  
Vol 41 (10) ◽  
pp. 836-843 ◽  
Author(s):  
Paolo Bossi ◽  
Nabil F. Saba ◽  
Jan B. Vermorken ◽  
Primoz Strojan ◽  
Laura Pala ◽  
...  
Keyword(s):  
Systemic Therapy ◽  
Critical Review ◽  
Sinonasal Cancer

scholarly journals Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy

2021 ◽  
Vol 91 (S2) ◽  
pp. 3-13
Author(s):  
B. Mark Smithers ◽  
Robyn P. M. Saw ◽  
David E. Gyorki ◽  
Richard C. W. Martin ◽  
Victoria Atkinson ◽  
...  
Keyword(s):  
New Zealand ◽  
Systemic Therapy ◽  
Advanced Melanoma ◽  
Adjuvant Systemic Therapy ◽  
Contemporary Management

scholarly journals 466 Resection or Enucleation for Extremely Giant Hepatic Haemangiomata? A Case Report and Review of The Literature

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
R E Fraser ◽  
G R Layton ◽  
L L Kuan ◽  
A R Dennison
Keyword(s):  
Expectant Management ◽  
Evidence Base ◽  
Primary Treatment ◽  
Cavernous Haemangioma ◽  
Liver Tumours ◽  
Case Presentation ◽  
Best Management ◽  
Anatomical Liver Resection ◽  
Benign Liver

Abstract Background Cavernous hepatic haemangiomas are benign liver tumours and although common when small, giant haemangiomas (usually accepted as being greater than 10cm) are infrequent. Treatment is indicated in patients who are symptomatic or if diagnosis is unclear, although with giant haemangiomas, many support expectant management of asymptomatic lesions due to the risk of major complications. Traditionally hepatic resection has been the primary treatment option for these lesions, but a variety of other techniques, including enucleation, have been described as safe and effective alternatives. There remains equipoise in respect of the best management of giant haemangiomas above 10cm. Cases of such size are rare and so there is a paucity of data available. Case presentation We present a case of a 65-year-old male who underwent successful anatomical liver resection for a 5kg giant cavernous haemangioma of 26cm diameter following its incidental identification during an ultrasound scan. We also discuss and compare the role of resection and enucleation for the treatment of haemangiomata greater than 20cm in diameter. Conclusions This case demonstrates successful resection of an unusually giant haemangioma which, in contrast to the majority of literature, provides a valuable addition to the limited evidence base for management of this condition by anatomical resection.

scholarly journals The role of systemic therapy for localised gastric cancer

2006 ◽  
Vol 17 ◽  
pp. x114-x121 ◽  
Author(s):  
N. Starling ◽  
D. Cunningham
Keyword(s):  
Gastric Cancer ◽  
Systemic Therapy

scholarly journals Role of topical steroid in primary treatment of childhood phimosis

2017 ◽  
Vol 5 (8) ◽  
pp. 3680
Author(s):  
Sanjay Changole ◽  
Smita Dhane ◽  
Nilesh Agrawal
Keyword(s):  
Partial Response ◽  
Prospective Observational Study ◽  
Topical Steroid ◽  
Primary Treatment ◽  
Therapy Failure ◽  
Traditional Treatment ◽  
Hygiene Practices ◽  
Number Of Patients ◽  
Good Hygiene

Background: Circumcision has been the traditional treatment for phimosis, but with some controversies due to complications. The current study was undertaken to evaluate the effectiveness of topical steroid therapy as primary treatment for childhood phimosis.Methods: A prospective observational study was conducted and a total of 100 patients (age- 3 to 12 years) of phimosis were enrolled. The management consisted of topical application of 0.05% betamethasone Ointment for 4 weeks. Those with partial response were advised additional 2 weeks of therapy. Failure to treatment cases were subsequently subjected to circumcision.Results: Total 100 patients were enrolled in the study. Out of 100 patients, 9 were excluded because of non-compliance and remaining 91 patients were studied and followed up. 85 cases out of 91 (93.4%) were declared a ‘success’; while remaining 6 (6.6%) were declared ‘failure’ and were subjected to circumcision. Of the 85 successfully treated; majority (70, 82.3%) responded within 4 weeks of treatment and 15 (17.6%) responded in 6 weeks. The highest number of patients who responded to treatment within 4 weeks were < 5 years of age (54, 93.1%) (p<0.05).Conclusions: Topical steroid (0.05% betamethasone ointment) is an effective, safe, conservative and non-surgical method of primary treatment of childhood Phimosis, especially when combined with good hygiene practices of foreskin with daily retraction and cleansing.

scholarly journals Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy

2018 ◽  
Vol 5 (8) ◽  
pp. 32
Author(s):  
Jiaxin Niu ◽  
Junle Zhou ◽  
Sara Lindebak ◽  
Fade Mahmoud
Keyword(s):  
Brain Metastasis ◽  
Systemic Therapy

Novel systemic therapies in the treatment of fibrolamellar carcinoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16161-e16161
Author(s):  
Sara Gottlieb ◽  
Ariel Gliksberg ◽  
Erik Schadde ◽  
Paul Kent
Keyword(s):  
Partial Response ◽  
Systemic Therapy ◽  
Clinical Remission ◽  
Objective Response ◽  
Progression Free Survival ◽  
Primary Treatment ◽  
Tumor Control ◽  
Multi Agent ◽  
Fibrolamellar Carcinoma ◽  
Systemic Therapies

e16161 Background: Fibrolamellar carcinoma (FLC) is an exceedingly rare liver cancer affecting children and young adults without underlying liver disease. Complete surgical resection is the primary treatment option, but recurrence is common. There are currently no established systemic therapies. We have treated patients in both the neoadjuvant and adjuvant setting with three novel combination therapies: 5-fluorouracil/interferon/nivolumab (“Triple Therapy” or TT), gemcitabine/oxaliplatin/lenvatinib (GOL), and nivolumab/lenvatinib/quercetin (NLQ). The purpose of this study was to evaluate objective responses and tolerability of three multi-agent systemic therapies in the treatment of FLC. Methods: Data from all patients with FLC who received TT, GOL, or NLQ between May 2018 and February 2021 were reviewed. Patients who received a minimum of six cycles of systemic therapy with follow up scans at least two months after initiation were assessed based on objective response, survival, and toxicity. Results: Twenty-nine patients with FLC who were treated with novel multi-agent systemic therapy were evaluable based on the above criteria. Median age at start of treatment was 20 (7-52; 16F, 12M, 1 non-disclosed). Twenty-three patients received one combination therapy (13 TT, 8 GOL, 2 NLQ), five received two different lines (3 TT/NLQ, 2 TT/GOL), and one patient received all three novel combinations. Between our 29 patients, they had relapsed 36 total times, and 11 had already tried 2+ systemic therapies. Best RECIST 1.1 objective response (clinical remission + partial response) and tumor control rate (clinical remission + partial response + stable disease) were 58%/95%, 55%/100%, and 33%/83% for TT, GOL, and NLQ respectively. The median longest Progression Free Survival (PFS) on any novel multi-agent regimen was 9 months (2-29; 9.5 for TT, 7 for GOL, 6.5 for NLQ), with 18 patients still receiving the therapy extending their PFS. Of those with previous relapses, 56% have a PFS longer than their previous longest remission and 69% have a PFS longer than their previous shortest time to relapse. Half of patients with previous relapses are still receiving the treatment responsible for their longest PFS. Fever, chills, and nausea were the most common adverse effects experienced throughout all three regimens. Seven patients experienced 1+ grade 3 adverse event. There were no toxic deaths or organ failure. Two patients died as a result of disease; their longest PFS (1 on GOL, 1 on TT) were nine and 10 months. Conclusions: FLC is a devastating cancer with patients often relapsing even after successful surgical remission. There is a strong need for effective and tolerable systemic therapies for those with unresectable, relapsed, progressive, or metastatic disease. We have had promising results in treating FLC and prolonging survival with minimal toxicities using novel multi-agent regimens.

Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma

2022 ◽  
Author(s):  
Paul R. Burchard ◽  
Alexander C. Chacon ◽  
Alexa Melucci ◽  
Anthony S. Casabianca ◽  
Subir Goyal ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Systemic Therapy ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Pancreatic Acinar Cell Carcinoma

Role of Systemic Therapy

2020 ◽  
pp. 255-272
Author(s):  
Shalabh Arora ◽  
Atul Sharma
Keyword(s):  
Systemic Therapy
Sign in / Sign up

Export Citation Format

Share Document